Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a 18.75 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $2.75 million which missed the analyst consensus estimate of $5.84 million by 52.84 percent. This is a 70.21 percent decrease over sales of $9.24 million the same period last year.